Biological Computing Startup BioMap Raises $100 Million in New Funding

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

TRENDING: China’s Tsingshan Looms Over Tesla’s $5 Billion in Indonesian Nickel Deals

LATEST: China’s Tsingshan Looms Over Tesla’s $5 Billion in Indonesian Nickel Deals; Kuaishou Sets Up New Management Committee, a Year After Massive Restructuring; Vivo Becomes Latest Chinese Smartphone-Maker Accused of Tax Evasion in India; Retailer Gome Upends E-Commerce Unit, Fires Staff; China Rolls Out Short-Message BeiDou Chip for Smartphones; China’s Game Approval List Again Leaves Out Tencent and NetEase; U.S. Expands Ban on Sales of Chipmaking Gear to China; China Semiconductor Fund Graft Scandal Widens as Another Executive Probed, Sources Say; Chinese Online Grocer Missfresh Shutters Core Business After Failing to Secure a Lifeline; Nasdaq-Traded Kingsoft Cloud Files for Dual Primary Listing in Hong Kong; Hog Cannibalism Clip Spotlights Grim Plight of China’s Pork Producers; Huawei Launches Ride-Hailing Platform in Challenge to Didi’s Dominance; China Tightens Grip on Ride-Hailing Platforms’ Data Practices; China to Start Pilot to Speed Up Online Game Approvals; Baidu, Pony.ai to Be First to Offer Driverless Robotaxis in Beijing; Chinese Biotech Duo Eyes $2.8 Billion Singapore Expansion; Huawei Steps Up Debt Financing With $593 Million Onshore Bond Sale; Geely Founder-Backed Auto Chip Startup SiEngine Raises $148 Million; Electric-Car Maker Sokon Raises $1 Billion in Stock Sale; Genuine Biotech Reports Unimpressive Results for Covid Pill

By Ding Yi / Aug 02, 2021 07:29 PM / Business & Tech

BioMap, a Chinese startup that uses biological computing technology to develop drugs, has raised more than $100 million in a series A funding round led by GGV Capital.

Biological computing is a technology that operates at the intersection of biology, engineering and computer science and that uses cells or their sub-component molecules such as DNA to perform functions traditionally performed by an electronic computer.

The round also attracted investors including Baidu, Legend Capital, Bluerun Ventures and Xianghe Capital, BioMap said in a statement on Saturday.

The Beijing-based company said that it will use the fresh capital to boost R&D of its biocomputing technology.

Co-founded by Baidu CEO Robin Li and former Baidu Ventures’ CEO Wei Liu last year, BioMap said that it will focus on developing therapies and medicines for tumors, autoimmune diseases and fibrotic diseases.

Contact reporter Ding Yi (yiding@caixin.com) and editor Heather Mowbray (heathermowbray@caixin.com)

Share this article

Open WeChat and scan the QR code